pharmaceuticals PM market analysis — 2026-09-02

Pharmaceutical sentiment this session is mixed, with safety concerns in cell therapy offsetting clinical and commercial progress elsewhere in the sector. Major companies have paused parts of their CAR-T programmes to reassess risk, a development that weighs on confidence in cell-therapy development more broadly.

Elsewhere the picture is steadier. Novartis has strengthened its multiple-sclerosis pipeline following a positive late-stage readout, sharpening its rivalry with Roche and pointing to continued investment in next-generation MS treatments. GSK is also advancing an mRNA influenza vaccine toward a late-stage trial, a sign that platform investment in mRNA has not slowed despite the broader caution around cell therapy.

Drug-pricing policy remains an open commercial variable. More biopharma companies are joining a most-favoured-nation pricing framework, and how that commitment is implemented could shape launch strategy and margin expectations across the sector.

Taken together, the session reflects a sector balancing renewed safety caution in one modality against continued pipeline and platform progress in others, with pricing policy adding a further layer of commercial uncertainty. This is informational market analysis only, not financial advice.